These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 23589145)
21. [Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer]. Wang SJ; Sun B; Pan SH; Chen H; Kong R; Li J; Xue DB; Bai XW; Jiang HC Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(7):530-4. PubMed ID: 20646665 [TBL] [Abstract][Full Text] [Related]
22. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607 [TBL] [Abstract][Full Text] [Related]
23. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152 [TBL] [Abstract][Full Text] [Related]
24. PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway. Yao N; Chen Q; Shi W; Tang L; Fu Y Mol Carcinog; 2019 Jul; 58(7):1291-1302. PubMed ID: 30968979 [TBL] [Abstract][Full Text] [Related]
25. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation. Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367 [TBL] [Abstract][Full Text] [Related]
26. [Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine]. Liu A; Hu YS; Wang ZH; Tang LL; Ke PY; Lin SZ Yao Xue Xue Bao; 2011 Feb; 46(2):146-52. PubMed ID: 21542284 [TBL] [Abstract][Full Text] [Related]
27. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572 [TBL] [Abstract][Full Text] [Related]
28. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion. Jiang C; Yi XP; Shen H; Li YX World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919 [TBL] [Abstract][Full Text] [Related]
29. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
30. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway. Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057 [TBL] [Abstract][Full Text] [Related]
31. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine. Liu F; Gore AJ; Wilson JL; Korc M PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315 [TBL] [Abstract][Full Text] [Related]
32. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669 [TBL] [Abstract][Full Text] [Related]
33. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Liau SS; Whang E Clin Cancer Res; 2008 Mar; 14(5):1470-7. PubMed ID: 18316571 [TBL] [Abstract][Full Text] [Related]
34. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling. Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896 [TBL] [Abstract][Full Text] [Related]
35. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924 [TBL] [Abstract][Full Text] [Related]
36. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Chen J; Ouyang ZG; Zhang SH; Zhen YS Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403 [TBL] [Abstract][Full Text] [Related]
37. CircRNA hsa_circ_0002577 accelerates endometrial cancer progression through activating IGF1R/PI3K/Akt pathway. Wang Y; Yin L; Sun X J Exp Clin Cancer Res; 2020 Aug; 39(1):169. PubMed ID: 32847606 [TBL] [Abstract][Full Text] [Related]
38. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Bharadwaj U; Marin-Muller C; Li M; Chen C; Yao Q Mol Cancer; 2011 Aug; 10():106. PubMed ID: 21880146 [TBL] [Abstract][Full Text] [Related]
39. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer. Husain K; Francois RA; Yamauchi T; Perez M; Sebti SM; Malafa MP Mol Cancer Ther; 2011 Dec; 10(12):2363-72. PubMed ID: 21971120 [TBL] [Abstract][Full Text] [Related]
40. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]